Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-02-06 4:32 pm Sale | 13G | ADDEX THERAPEUTICS LTD ADS ADXN | New Leaf Biopharma Opportunities I L.P. | 2,316,293 3.000% | -50,000 (-2.11%) | View |
| 2022-02-18 4:54 pm Unchanged | 13G | ADDEX THERAPEUTICS LTD ADS ADXN | New Leaf Biopharma Opportunities I L.P. | 2,366,293 6.200% | 0 (Unchanged) | View |
| 2022-02-11 4:57 pm Unchanged | 13G | Sierra Oncology Inc. SRRA | New Leaf Biopharma Opportunities I L.P. | 787,414 4.100% | 0 (Unchanged) | View |
| 2022-02-11 4:48 pm Purchase | 13G | ADDEX THERAPEUTICS LTD ADS ADXN | New Leaf Biopharma Opportunities I L.P. | 2,366,293 4.500% | 50,000 (+2.16%) | View |
| 2021-02-10 5:30 pm Purchase | 13G | ADDEX THERAPEUTICS LTD ADS ADXN | New Leaf Biopharma Opportunities I L.P. | 2,316,293 7.100% | 2,316,293 (New Position) | View |
| 2020-02-12 5:42 pm Purchase | 13G | Sierra Oncology Inc. SRRA | New Leaf Biopharma Opportunities I L.P. | 787,414 7.300% | 787,414 (New Position) | View |